Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated
   locally advanced or metastatic urothelial carcinoma (mUC): Immune
   biomarkers, tumor mutational burden (TMB), and clinical outcomes from
   the phase III IMvigor211 study.

Titel:: Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Dokumenttyp:: Meeting Abstract
Autor(en):: Powles, Thomas; Loriot, Yohann; Ravaud, Alain; Vogelzang, Nicholas J.; Duran, Ignacio; Retz, Margitta; De Giorgi, Ugo; Oudard, Stephane; Bamias, Aristotelis; Koeppen, Hartmut; Leng, Ning; Kadel, Edward E.; Hegde, Priti S.; Cui, Na; Shen, Xiaodong; Derleth, Christina Louise; Green, Marjorie C.; Banchereau, Romain; Mariathasan, Sanjeev; Van Der Heijden, Michiel Simon
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2018
Band / Volume:: 36
Heft / Issue:: 6
Volltext / DOI:: doi:10.1200/JCO.2018.36.6_suppl.409
Print-ISSN:: 0732-183X
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: